HCM and New Pharmacological Agents
06/27/22 • 37 min
Making the correct of hypertrophic cardiomyopathy (HCM) is critical in being able to initiate early surveillance and therapy to improve patient outcomes. In this podcast focusing on pharmacologic treatment options, learn more about completed and ongoing myosin inhibitor clinical trials.
Making the correct of hypertrophic cardiomyopathy (HCM) is critical in being able to initiate early surveillance and therapy to improve patient outcomes. In this podcast focusing on pharmacologic treatment options, learn more about completed and ongoing myosin inhibitor clinical trials.
Previous Episode
Beware! Phenocopies of Hypertrophic Cardiomyopathy
Accurate diagnosis of Hypertrophic Cardiomyopathy (HCM) is critical. HCM is a chronic and progressive disease putting patients at risk of serious complications and co-morbidities. Early and correct detection may help reduce some of the consequences of HCM and improve outcomes. In this podcast, learn more about how to distinguish phenocopies from HCM.
Next Episode
Needle in the Haystack? Screening Large Populations for HCM
It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Listen to this podcast to gain insight into hypertrophic cardiomyopathy (HCM) screening and what it means to your patients.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/hypertrophic-cardiomyopathy-podcast-series-518753/hcm-and-new-pharmacological-agents-67692430"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to hcm and new pharmacological agents on goodpods" style="width: 225px" /> </a>
Copy